The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck KGaA
PERSPECTIVE: Tepotinib + cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Exact Sciences; Foundation Medicine; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - AstraZeneca; Exelixis; Lilly; Merck (Inst); Pancreatic Cancer Action Network
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Antonio Cubillo
No Relationships to Disclose
 
Caroline Petorin-Lesens
No Relationships to Disclose
 
Nuria Rodriguez-Salas
No Relationships to Disclose
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Eisai
 
Olivier Dupuis
No Relationships to Disclose
 
Carlos López-López
Honoraria - Advanced Accelerator Applications; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Merck; MSD Oncology; Novartis; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Eisai; Ipsen; Merck; Pfizer; Roche; Sanofi; SERVIER
Research Funding - Amgen; AstraZeneca Spain; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Merck Sharp & Dohme; Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; Ipsen; Merck; Pfizer; Roche; SERVIER
 
Christophe Tournigand
Honoraria - Bayer; Bristol-Myers Squibb; MSD; Roche; Sanofi
Consulting or Advisory Role - Bayer
Research Funding - Roche
Travel, Accommodations, Expenses - Bayer; MSD; Roche
 
Nicolas Isambert
Consulting or Advisory Role - Daichii; Ipsen; Pfizer; Transgene
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar
 
Khalid Abubaker
Employment - Merck KGaA
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Advaxis; Cardiff Oncology; Cormedix; Merck KGaA
 
Karl-Maria Schumacher
No Relationships to Disclose
 
Karin Berghoff
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Soetkin Vlassak
Employment - Merck
Honoraria - Merck
 
Gordon Otto
Employment - Merck KGaA
Stock and Other Ownership Interests - Novartis
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Avvinity; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Seagen; Servier; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc
Other Relationship - Imedex; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource